Q1 Earnings In Brief: Celgene, Alkermes, Novo Nordisk, Acorda, Alexion
Executive Summary
First quarter earnings are in full swing. Here is a look at what some companies are saying to analysts during their quarterly calls. Celgene talks up Revlimid; Alkermes bullish on Aristada launch; Victoza market share threatened by Trulicity; Acorda plans for Phase III in post-stroke; Soliris still backbone at Alexion.